BIOTRONIK Sets New Clinical Benchmark with Ultrathin Strut Orsiro Coronary Drug-Eluting Stent

Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro's Position as the Clinical Benchmark for DES

News provided by

BIOTRONIK

Feb 28, 2022, 09:00 ET

BÜLACH, Switzerland, Feb. 28, 2022 /PRNewswire/ -- BIOTRONIK is pleased to announce five-year data from the BIOFLOW-V trial, which was presented yesterday at the 2022 CRT Conference during a late-breaking clinical trial session by Dr. David Kandzari, US Principal Investigator, Piedmont Heart Institute, Atlanta, Georgia.

The five-year follow-up data demonstrates consistently lower clinical event rates in target lesion failure (TLF) and significantly lower rates of target-vessel myocardial infarction (TV-MI). This reinforces the body of evidence differentiating Orsiro® DES from other contemporary DES making it the first and only ultrathin strut DES proven to outperform Xience DES.^1,2 Orsiro DES received FDA approval in 2019 and has been used to treat more than three million patients worldwide to date. The latest generation of BIOTRONIK's DES, Orsiro® Mission gained FDA approval in 2021 and benefits from the same stent as its predecessor device with a reengineered delivery system for even better deliverability*.

"The final five-year follow-up data confirms Orsiro's superior safety profile and low TLF rates," said Dr. David Kandzari. "The ultrathin strut Orsiro stent significantly reduces the risk for TV-MI and shows a low rate of stent thrombosis (ST), and specifically a significant reduction in late and very late stent thrombosis. These long-term results confirm that the Orsiro DES sets a new clinical benchmark in PCI treatment options."

Orsiro's clinical performance in the pivotal BIOFLOW-V trial (n=1,334)² has already demonstrated significantly lower rates for TLF and TV-MI compared to Xience DES at 12 months follow up and continued to show significant differences across the most important secondary endpoints at 36 months follow-up.³

View BIOFLOW-V 5-year results chart here.⁴

"The final BIOFLOW-V data clearly shows that Orsiro provides better patient outcomes in this head-to-head comparison against Xience DES," said Ryan Walters, President at BIOTRONIK, Inc. "With the newly launched Orsiro Mission DES available in the U.S. we have the same clinical performance with next level deliverability making it a 'must have' in every cath-lab."

BIOFLOW-V is the first large randomized trial to show improved long-term outcomes in the field of DES over Xience DES. The international study included 1,334 patients, of which a sizable percentage were complex: 50.8%⁵ of patients presented with acute coronary syndrome (ACS), 35.0%⁵ of patients were diabetic, and 73.8%⁶ of lesions were ACC/AHA Class B2/C.

*Clinical data conducted with Orsiro, Orsiro Mission's predecessor device can be used to illustrate Orsiro Mission clinical data.

**BIOTRONIK data on file, status as per January 2020

Orsiro and Orsiro Mission are trademarks or registered trademarks of the BIOTRONIK Group of Companies.

References:
¹Xience is a trademark or registered trademark of the Abbott Group of Companies.
²Kandzari D et al. The Lancet. 2017, 390(10105).
³Kandzari D et al. J Am Coll Cardiol. Cardiovasc Interven. 2020, doi: 10.1016/j.jcin.2020.02.019.
⁴Kandzari D presented at CRT 2022 – Late Breaking Clinical Trial February 27th, 2022, Late Breaking Trials: Session I
⁵Kandzari et al, Supplement to: Kandzari DE, Mauri L, Koolen JJ et al. Ultrathin Bioresorbable Polymer Sirolimus-Eluting
Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularisation
(BIOFLOW V): a randomised trial, JACC, 2017
⁶Kandzari, BIOFLOW V – Comparison of ultrathin sirolimus eluting bioresorbable polymer with thin everolimus eluting
durable polymer stents, Presented at ESC Congress, Barcelona, 2017

For indications please see Instructions For Use.

For more information, visit:
www.biotronik.com

About BIOTRONIK:
BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries.

Learn more about Orsiro and Orsiro Mission here

Follow us on: